Compare Novartis AG (NVS) vs Ross Stores, Inc. (ROST) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Ross Stores (ROST) trades at $229.31, down 0.6% on the day, showing bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.66 beating expectations by 36%. Revenue growth accelerated to 13% in Q2 2026, with comparable store sales surging 10% driven by increased traffic and margin expansion. The stock faces technical resistance near $234 while maintaining strong analyst support with a $271.33 consensus price target.

ROST presents a compelling growth story with robust fundamentals but faces near-term technical headwinds. The company's value-focused retail strategy resonates with cost-conscious consumers, driving consistent earnings outperformance. Key risks include competitive pressures in off-price retail and macroeconomic sensitivity. With 64% of analysts maintaining buy ratings and a 19% upside to consensus targets, the stock offers growth potential for investors comfortable with current technical weakness.